Rockefeller Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

Rockefeller Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$285K	Buy	+3,675	New	+$251K	﹤0.01%	317

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Rockefeller Financial Services's NBIX Position: Q4 2017 in Review

Rockefeller Financial Services opened a new position in Neurocrine Biosciences (NBIX) in Q4 2017: 3,675 shares worth $285K. The stake represents ﹤0.01% of the portfolio and ranks #317 among its holdings.

267 funds tracked by Wall St. Rank hold NBIX as of Q4 2017.

Rockefeller Financial Services held 3,675 shares of Neurocrine Biosciences worth $285K as of Q4 2017.
Neurocrine Biosciences was a new Rockefeller Financial Services position in Q4 2017.
Neurocrine Biosciences made up ﹤0.01% of Rockefeller Financial Services's portfolio in Q4 2017, its #317 holding.
267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2017.

Based on Rockefeller Financial Services's 13F filing for Q4 2017, filed 2 Feb 2018.